Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Nat Cancer. 2021 Dec;2(12):1321-1337. doi: 10.1038/s43018-021-00275-9. Epub 2021 Oct 27.
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4 responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
癌症患者 COVID-19 的发病率和死亡率更高。在这里，我们介绍了前瞻性 CAPTURE 研究，该研究将纵向免疫分析与临床注释相结合。在 357 名癌症患者中，有 118 名 SARS-CoV-2 阳性，94 名有症状，2 名死于 COVID-19。在该队列中，83%的患者对 S1 有反应性抗体，82%的患者对野生型 SARS-CoV-2 有中和抗体，而对 Alpha、Beta 和 Delta 变体的中和抗体滴度显著降低。13%的患者 S1 反应性抗体水平下降，而中和抗体滴度在长达 329 天内保持稳定。患者还具有可检测到的 SARS-CoV-2 特异性 T 细胞和 CD4 反应，与 S1 反应性抗体水平相关，尽管血液恶性肿瘤患者的免疫反应受损，但具有疾病和治疗特异性，但存在代偿性细胞反应，这进一步得到了所有患者（除 1 例外）临床康复的支持。总体而言，这些发现推进了我们对癌症患者对 SARS-CoV-2 免疫反应的性质和持续时间的理解。
